Patient selection? One fits all (monotherapy versus combined therapy)? Source: Sleep and Breathing Conference 2021 Year: 2021
Three drug regimen in SCLC-ED patients: a phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006
Development of multi-drug resistant tuberculosis among patients treated with category II regimen: A lung center of the Philippines experience Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
The treatment results in previously treated patients with standard category 2 regimen Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003
Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure Year: 2018
Second line chemotherapy with cisplatin (C) plus paclitaxel (P) for chemo refractory and resistant SCLC patients (pts). Did it change the overall disease’s prognosis? Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001
Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017
Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011
Con: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Source: Breathe, 17 (2) 210049; 10.1183/20734735.0049-2021 Year: 2021
Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Source: Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021 Year: 2021
Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Individualized treatment regimens with second line anti-TB drugs (SLD) compared to first line anti-TB drug (FLD) only in new pulmonary TB patients, culture confirmed with full sensibility at drug sensibility test (DST) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011